Literature DB >> 29143014

Synthesis, characterization, and anticancer activity of two mixed ligand copper(ii) complexes by regulating the VEGF/VEGFR2 signaling pathway.

Xiu-Ying Qin1, Ya-Nan Wang2, Xin-Ping Yang2, Juan-Juan Liang2, Ji-Lin Liu2, Zhao-Hui Luo2.   

Abstract

The single crystals of two novel mixed-ligand copper(ii)-based complexes were obtained and characterized. These complexes can remarkably induce apoptosis, inhibit proliferation, suppress migration and metastasis, and inhibit angiogenesis to inhibit the growth of cervical cancer by down-regulating the expressions of the important proteins FAK, Akt and Erk1/2 or their phosphorylated proteins p-FAK, p-Akt, and p-Erk1/2 downstream of the VEGF/VEGFR2 signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29143014     DOI: 10.1039/c7dt03242k

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  3 in total

1.  Tetramethyl-phenanthroline copper complexes in the development of drugs to treat cancer: synthesis, characterization and cytotoxicity studies of a series of copper(II)-L-dipeptide-3,4,7,8-tetramethyl-phenanthroline complexes.

Authors:  Natalia Alvarez; Celisnolia M Leite; Adriana Napoleone; Luis F S Mendes; Carlos Y Fernández; Ronny R Ribeiro; Javier Ellena; Alzir A Batista; Antonio J Costa-Filho; Gianella Facchin
Journal:  J Biol Inorg Chem       Date:  2022-05-07       Impact factor: 3.862

2.  Tetranuclear Cu(ii)-chiral complexes: synthesis, characterization and biological activity.

Authors:  Krisana Peewasan; Marcel P Merkel; Kristof Zarschler; Holger Stephan; Christopher E Anson; Annie K Powell
Journal:  RSC Adv       Date:  2019-08-02       Impact factor: 4.036

3.  Epithelial-mesenchymal transition and metastasis of colon cancer cells induced by the FAK pathway in cancer-associated fibroblasts.

Authors:  Xuefeng Xuefeng; Ming-Xing Hou; Zhi-Wen Yang; Agudamu Agudamu; Feng Wang; Xiu-Lan Su; Xian Li; Lin Shi; Terigele Terigele; Li-Li Bao; Xin-Lin Wu
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.